SANTIAGO-VITERI

Santiago Viteri Ramírez

Especialidad: Oncología Médica
Especialidad: Oncología
Hospitales donde trabaja:
  • Centro Médico Teknon
Especialidades que atiende:
  • Oncología

El Dr. Viteri se licenció en el año 2002 en Medicina por la Universidad de Navarra y el 2007 obtuvo la especialización en Oncología en la misma universidad. Su área de especialización se centra en el cáncer de pulmón.

Experiencia
  • Desde el 2016 Jefe clínico de la División de Oncología Médica en Instituto Oncológico Rosell
  • 2010-2015 Coordinador clínico de Instituto Oncológico Rosell en Hospital Dexeus (Barcelona)
  • 2008– 2010 Oncólogo médico en Instituto Oncológico Rosell en Hospital Dexeus (Barcelona)
  • 2007-2008 Oncólogo medico en Hospital General Mateu Orfila (Menorca)
Pertenencia a Sociedades Médicas
  • GECP (Grupo Españo de Cáncer de Pulmón)
  • ASCO (American Society of Clínical Oncology)
  • ESMO (European Society of Medical Oncology)
  • IASLC (International Association of Lung Cancer)

Investigador principal en + 30 ensayos fases I, II y III en cáncer de pulmón


Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. Viteri S, González-Cao M, Barrón F, Riso A, Rosell R. Transl Lung Cancer Res 2015;4(6):756-762. doi: 10.3978/j.issn.2218-6751.2015.12.06.

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. Sci Rep. 2015 Dec 7;5:17499. doi:10.1038/srep17499. PubMed PMID: 26639561; PubMed Central PMCID: PMC4671004.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study Ou SI, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. J Clin Oncol. 2015 Nov 23. pii: JCO639443. [Epub ahead of print] PubMed PMID: 26598747.

Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors. Goel S, Viteri S, Morán T, Coronado C, Dios JL, Miguel-Lillo B, Fernández-García EM, Rosell R. Invest New Drugs. 2015 Dec 2. [Epub ahead of print] PubMed PMID: 26627080.

Other targeted drugs in melanoma. González-Cao M, Rodón J, Karachaliou N, Sánchez J, Santarpia M, Viteri S, Pilotto S, Teixidó C, Riso A, Rosell R. Ann Transl Med. 2015 Oct;3(18):266. doi: 10.3978/j.issn.2305-5839.2015.08.12. Review. PubMed PMID: 26605312; PubMed Central PMCID: PMC4630555.

Melanoma: oncogenic drivers and the immune system. Karachaliou N, Pilotto S, Teixidó C, Viteri S, González-Cao M, Riso A, Morales-Espinosa D, Molina MA, Chaib I, Santarpia M, Richardet E, Bria E, Rosell R. Ann Transl Med. 2015
Oct;3(18):265. doi: 10.3978/j.issn.2305-5839.2015.08.06. Review. PubMed PMID: 26605311; PubMed Central PMCID: PMC4630557.

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Nilsson RJ, Karachaliou N, Berenguer J, Gimenez-Capitan A, Schellen P, Teixido C, Tannous J, Kuiper JL, Drees E, Grabowska M, van Keulen M, Heideman DA, Thunnissen E, Dingemans AC, Viteri S, Tannous BA, Drozdowskyj A, Rosell R, Smit EF, Wurdinger T. Oncotarget. 2015 Nov 2. doi: 10.18632/oncotarget.6279. [Epub ahead of print] PubMed PMID: 26544515.

Advances in immunotherapy for treatment of lung cancer. Bustamante Alvarez JG, González-Cao M, Karachaliou N, Santarpia M, Viteri S, Teixidó C, Rosell R. Cancer Biol Med. 2015 Sep;12(3):209-22. doi: 10.7497/j.issn.2095-3941.2015.0032. Review. PubMed PMID: 26487966; PubMed Central PMCID: PMC4607819.

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL, Cortes J, Berros JP, Drozdowskyj A, Sanmamed M, Gonzalez A, Alvarez C, Viteri S, Karachaliou N, Martin Algarra S, Bertran-Alamillo J, Jordana-Ariza N, Rosell R. Melanoma Res. 2015 Dec;25(6):486-95. doi: 10.1097/CMR.0000000000000187. PubMed PMID: 26366702.

Spanish Lung Cancer Group. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R; JAMA Oncol. 2015 May;1(2):149-57. doi: 10.1001/jamaoncol.2014.257. PubMed PMID: 26181014.

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. Karachaliou N, Cao MG, Teixidó C, Viteri S, Morales-Espinosa D, Santarpia M, Rosell R. Cancer Biol Med. 2015 Jun;12(2):79-86. doi: 10.7497/j.issn.2095-3941.2015.0029. Review. PubMed PMID: 26175923; PubMed Central PMCID: PMC4493378.

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J. Oncotarget. 2015 Apr 30;6(12):10577-85. PubMed PMID: 25868855; PubMed Central PMCID: PMC4496376.

A critical question for cancer therapy: what new targets exist?Rosell R, Karachaliou N, Codony J, Teixido C, Garcia-Roman S, Morales D, Cao MG, Viteri S, Veliz I, Loo Y, Castillo O. Transl Lung Cancer Res. 2014 Dec;3(6):384-8. doi: 10.3978/j.issn.2218-6751.2014.08.10. PubMed PMID: 25806328; PubMed Central PMCID: PMC4367674.

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, Viteri S, Moran T, Carcereny E, Massuti B, Vergnenegre A, de Marinis F, Molina MA, Teixido C, Rosell R. Transl Lung Cancer Res. 2014 Jun;3(3):122-30. doi: 10.3978/j.issn.2218-6751.2014.03.02. PubMed PMID: 25806291; PubMed Central PMCID: PMC4367691.

Predicting resistance by selection of signaling pathways.Karachaliou N, Rosell R, Molina MA, Viteri S. Transl Lung Cancer Res. 2014 Apr;3(2):107-15. doi: 10.3978/j.issn.2218-6751.2014.02.04. Review. PubMed PMID: 25806289; PubMed Central PMCID: PMC4367662.

Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Molina-Vila MA, Bertran-Alamillo J, Gascó A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto AG, Cardona AF, Vergnenègre A, Majem M, Massuti B, Morán T, Carcereny E, Viteri S, Rosell R. Clin Cancer Res. 2014 Sep 1;20(17):4647-59. doi: 10.1158/1078-0432.CCR-13-2391. Epub 2014 Apr 2. PubMed PMID: 24696321.

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Karachaliou N, Rosell R, Morales-Espinosa D, Viteri S. Expert Rev Anticancer Ther. 2014 Jul;14(7):807-15. doi: 10.1586/14737140.2014.896210. Epub 2014 Mar 10. Review. PubMed PMID: 24611674.

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. Clin Cancer Res. 2014 Apr 1;20(7):2001-10. doi: 10.1158/1078-0432.CCR-13-2233. Epub 2014 Feb 3. PubMed PMID: 24493829.

Signaling pathways modulating dependence of lung cancer on mutant epidermal growth factor receptor and mechanisms of intrinsic and acquired resistance to tyrosine kinase inhibitors. Wannesson L, Viteri S, Costa C, Karachaliou N, Molina-Vila MA, Rosell R. Curr Pharm Des. 2014;20(24):3883-93. Review. PubMed PMID: 24138718.

BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.Sánchez-Torres JM, Viteri S, Molina MA, Rosell R. Transl Lung Cancer Res. 2013 Jun;2(3):244-50. doi: 10.3978/j.issn.2218-6751.2013.04.01. Review. PubMed PMID: 25806238; PubMed Central PMCID: PMC4367599.

The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung. Karachaliou N, Rosell R, Viteri S. Transl Lung Cancer Res. 2013 Jun;2(3):172-9. doi: 10.3978/j.issn.2218-6751.2013.01.01. Review. PubMed PMID: 25806230; PubMed Central PMCID: PMC4367598.

Adaptive resistance to targeted therapies in cancer.Rosell R, Karachaliou N, Morales-Espinosa D, Costa C, Molina MA, Sansano I, Gasco A, Viteri S, Massuti B, Wei J, González Cao M, Martínez Bueno A. Transl Lung Cancer Res. 2013 Jun;2(3):152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08. Review. PubMed PMID: 25806228; PubMed Central PMCID: PMC4367602.

CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors. Mayo C, Ortega FG, Giménez-Capitán A, Molina-Vila MA, Serrano MJ, Viteri S, Costa C, Gascó A, Bertran-Alamillo J, Karachaliou N, Lorente JA, Tarón M, Rosell R. Transl Lung Cancer Res. 2013 Apr;2(2):65-71. doi: 10.3978/j.issn.2218-6751.2013.02.06. PubMed PMID: 25806217; PubMed Central PMCID: PMC4369853.

Spanish Lung Cancer Group. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.Karachaliou N, Costa C, Gimenez-Capitan A, Molina-Vila MA, Bertran-Alamillo J, Mayo C, Massuti B, Majem M, Carcereny E, Moran T, Sanchez JJ, Viteri S, Gasco A, Wannesson L, Souglakos J, Jimeno J, Rosell R; J Thorac Oncol. 2013 Mar;8(3):295-300. doi: 10.1097/JTO.0b013e31827db621. PubMed PMID: 23407556.

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients.Santarpia M, Magri I, Sanchez-Ronco M, Costa C, Molina-Vila MA, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Benlloch S, Viteri S, Gasco A, Mederos N, Carcereny E, Taron M, Rosell R. J Transl Med. 2011 Sep 27;9:163. doi:10.1186/1479-5876-9-163. PubMed PMID: 21951562; PubMed Central PMCID: PMC3203857.

Evaluation of multiple serum markers in advanced melanoma. Díaz-Lagares A, Alegre E, Arroyo A, González-Cao M, Zudaire ME, Viteri S, Martín-Algarra S, González A. Tumour Biol. 2011 Dec;32(6):1155-61. doi: 10.1007/s13277-011-0218-x.Epub 2011 Aug 20. PubMed PMID: 21858537.

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M. Clin Cancer Res. 2011 Mar 1;17(5):1160-8. doi: 10.1158/1078-0432.CCR-10-2158. Epub 2011 Jan 13. PubMed PMID: 21233402.

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. Simonetti S, Molina MA, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, Sanchez JJ, Gonzalez-Larriba JL, Jimenez U, Isla D, Moran T, Viteri S, Camps C, Garcia-Campelo R, Massuti B, Benlloch S, Ramon y Cajal S, Taron M, Rosell R. J Transl Med. 2010 Dec 18;8:135. doi: 10.1186/1479-5876-8-135. PubMed PMID: 21167064; PubMed Central PMCID: PMC3016260.

Predictive biomarkers in the management of EGFR mutant lung cancer. Rosell R, Moran T, Cardenal F, Porta R, Viteri S, Molina MA, Benlloch S, Taron M. Ann N Y Acad Sci. 2010 Oct;1210:45-52. doi: 10.1111/j.1749-6632.2010.05775.x. PubMed PMID: 20973798.

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. Rosell R, Moran T, Viteri S, Carcereny E, Gasco A, Quiroga V, Wei J, Camps C, Massuti B. Expert Opin Pharmacother. 2010 Jul;11(10):1683-93. doi: 10.1517/14656566.2010.482101. Review. PubMed PMID: 20486827.

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Curr Opin Oncol. 2010 Mar;22(2):112-20. doi:10.1097/CCO.0b013e32833500d2. Review. PubMed PMID: 19949333.

Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma, González-Cao M, Viteri S, Díaz-Lagares A, González A, Redondo P, Nieto Y, Espinós J, Chopitea A, Ponz M, Martín-Algarra S. Oncology.2008;74(1-2):12-6. doi: 10.1159/000138351. Epub 2008 Jun 9. PubMed PMID: 18536525.

Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. Nieto Y, Aldaz A, Rifón J, Pérez-Calvo J, Zafra A, Zufia L, Viúdez A, Viteri S, Aramendía JM, Aristu J, Centeno C, Moreno M, Sayar O, Hernández M. Biol Blood Marrow Transplant. 2007 Nov;13(11):1324-37. Epub 2007 Sep 7. PubMed PMID:17950919.

[Small-cell lung cancer]. Pérez-Gracia JL, López-Picazo JM, Martín-Algarra S, Viteri S, García-Foncillas J, Gúrpide A. Rev Med Univ Navarra. 2007 Apr-Jun;51(2):7-13. Review. Spanish. PubMed PMID: 17886708.

[Mammographic findings in microcalcifications associated with breast cancer after neoadjuvant chemotherapy]. Noguera JJ, de Luis E, Alonso-Burgos A, Viteri S, Zornoza G, Pina L. Radiologia. 2007 Jan-Feb;49(1):37-41. Spanish. PubMed PMID: 17397619.

Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab. González Cao M, Viteri S, Garrán C, Nieto Y, Aristu J, Ponz M, Martín Algarra S. Clin Transl Oncol. 2007 Feb;9(2):119-20. PubMed PMID: 17329225.


Publication Only

ASCO 2015

Santiago Viteri Ramirez, Clara Mayo-de las Casas, Nuria Jordana-Ariza, Daniela Morales-Espinosa, Miguel Angel Molina-Vila, Niki Karachaliou, Maria Gonzalez Cao, Marc Simo-Perdigo, Jordi Bertran-Alamillo, Jordi Codony, Monica Garzon, Ana Perez-Rosado, Alejandro Martinez-Bueno, Xavier Gonzalez, Elena Ovalle, Rafael Rosell; Serial mutational analysis to monitor disease evolution in blood from advanced non small cell lung cancer (NSCLC) patients (p)

Daniela Morales-Espinosa, Miguel Angel Molina-Vila, Ana Gimenez Capitan, Silvia Garcia-Roman, Jordi Bertran-Alamillo, Pedro Mendez, Jose Luis Ramirez-Serrano, Carles Codony, Santiago Viteri Ramirez, Niki Karachaliou, Rafael Rosell; Analysis of gene expression in the re-replication pathway and selective blockade with checkpoint inhibitors as a potential therapeutic option in NSCLC.

ASCO 2013
Maria Gonzalez Cao, Carlota Costa, Miguel Angel Molina-Vila, Maria Teresa Cusido, Santiago Viteri Ramirez, Sonia Baulies, Alejandro Martinez-Bueno, Rafael Fabregas, Francesc Tresserra, Irene Sansano, Carmen Ara, David Amselen, Belen Ubeda, Marc Simo-Perdigo, Amaya Gasco, Ignacio Rodriguez, Rafael Rosell; Molecular analysis in breast cancer subtypes and correlation with pathologic complete response (pCR) to neoadjuvant chemotherapy.

ASCO 2012
Amaya Gasco, Miguel Angel Molina-Vila, Jordi Bertran-Alamillo, Clara Mayo, Carlota Costa, Ana Gimenez Capitan, Bartomeu Massuti, Carlos Camps, Enric Carcereny Costa, Santiago Viteri Ramirez, Alejandro Martinez-Bueno, Susana Benlloch, Laia Capdevila, Sara Cros, Rut Porta, Felipe Cardenal, Joaquim Bosch, Jose Javier Sanchez, Miquel Taron, Rafael Rosell; Association of p53 mutations with progression-free survival (PFS) and overall survival (OS) in EGFR-mutated non-small cell lung cancer (NSCLC) patients (p) treated with erlotinib

Santiago Viteri Ramirez, Carlota Costa, Ana Gimenez Capitan, Susana Benlloch, Miquel Taron, Jose Javier Sanchez, Amaya Gasco, Alejandro Martinez-Bueno, Niki Karachaliou, Carlos Camps, Teresa Moran, Enric Carcereny Costa, Bartomeu Massuti, Felipe Cardenal, Rut Porta, Joaquim Bosch, Ramon Palmero, Cristina Buges, Rafael Rosell; High mRNA expression of LMO4, a BRCA1 downregulator, correlates with better prognosis in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.

M. Rosario Garcia-Campelo, Miquel Taron, Susana Benlloch, Jose Javier Sanchez, Carlota Costa, Ana Gimenez Capitan, Jordi Bertran-Alamillo, Clara Mayo, Miguel Angel Molina-Vila, Margarita Majem, Teresa Moran, Bartomeu Massuti, Carlos Camps, Dolores Isla, Manuel Cobo, Sara Cros, Laia Capdevila, Enric Carcereny Costa, Santiago Viteri Ramirez, Rafael Rosell; MCPH1 (BRIT1) and outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) harboring EGFR mutations.

ASCO 2011
I. Magri, M. Santarpia, M. Sanchez-Ronco, S. Viteri, C. Costa, A. Gasco, N. Mederos, M. Gonzalez Cao, F. Salazar, J. Bertran-Alamillo, A. Gimenez Capitan, M. A. Molina, Z. Yeste, E. Aldeguer, T. Moran, G. Altavilla, S. Benlloch, M. Taron, R. Rosell; Differential expression of BRCA1 and genes involved in the nuclear factor kappa B (NFκB) and notch signalling pathways in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients (p).

ASCO 2010
M. A. Molina, S. Simonetti, V. Quiroga, S. Viteri, R. G. Campelo, J. Sanchez, S. Benlloch, E. Aldeguer, M. Taron, R. Rosell; Survivin and CrkL expression in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.

Más de 40 conferencias en los siguientes temas: cáncer de pulmón, medicina de precisión, biología molecular del cáncer, inmunoterapia en cáncer

International Meetings

ORAL PRESENTATION

ASCO 2015
Sai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih-Hsin Yang, Brett Gordon Maxwell Hughes, Hervé Lena, Denis Moro-Sibilot, Alessandra Bearz, Santiago Viteri Ramirez, Tarek Mekhail, Alexander I. Spira, Ali Hassan Zeaiter, Walter Bordogna, Bogdana Balas, Sophie Golding, Peter N. Morcos, Dong-Wan Kim; Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673).

World Meeting of Melanoma Centers 2007
S. Viteri, M. Gonzalez Cao, A. Diaz Lagarés, A. Chopitea, P. Redondo, S. Martín Algarra, A. González. Análisis of multiple serum markers in advanced melanoma.

POSTER DISCUSSION

ASCO 2013
Enric Carcereny Costa, Jordi Bertran-Alamillo, Miguel Angel Molina-Vila, Radj Gervais, Bartomeu Massuti, Laura Bonanno, Teresa Moran, Margarita Majem, Enriqueta Felip, M. Rosario Garcia-Campelo, Alain Vergnenegre, Santiago Viteri Ramirez, Amaya Gasco, Luciano Wannesson, Clara Mayo-de las Casas, Laia Pujantell-Pastor, Adolfo G. Favaretto, Niki Karachaliou, Rafael Rosell, Nondisruptive mutations of TP53 and overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients (p)

Amaya Gasco, Pedro Mendez, Jose Luis Ramirez, Santiago Viteri Ramirez, Teresa Moran, Enric Carcereny Costa, Carlota Costa, Ana Gimenez Capitan, Irene Sansano, Maria Perez, Montserrat Tierno, Monica Botia, Miquel Taron, Harry J.M. Groen, Rafael Rosell, Fibroblast growth factor receptor 1 (FGFR1) and SRY-related HMG-box (SOX2) amplification in squamous cell carcinoma (SCC) of the lung

Niki Karachaliou, Ana Drozdowskyj, Carlota Costa, Miguel Angel Molina-Vila, Ana Gimenez Capitan, Alain Vergnenegre, Bartomeu Massuti, Teresa Moran, Margarita Majem, Enriqueta Felip, Enric Carcereny Costa, M. Rosario Garcia-Campelo, Santiago Viteri Ramirez, Cordula Nicole Heidecke, Roger Estrada-Tejedor, Jordi Teixido, Trever Grant Bivona, Petros Giannikopoulos, Mayumi Ono, Rafael Rosell, ROR1 mRNA expression in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with the T790M mutation: A potential therapeutic target.

ASCO 2017
S. Viteri, A. Diaz-Lagares, A. González, S. Martin Algarra, P. Redondo, J. Espinos, M. Gonzalez Cao. "VEGF serum levels during bevacizumab plus paclitaxel combination in metastatic melanoma".

ESMO 2006
M. Gonzalez Cao, S. Viteri, A. Chopitea, Y. Nieto, A. González, J.M. Aramendía, P. Redondo, M.A. Idoate, D. Aquerreta, S. Martín-Algarra. "Bevacizumab and weekly taxol combination in previously treated metastatic melanoma patients".

POSTER

ASCO2015
Alejandro Martinez-Bueno, Sonia Baulies, Miguel Angel Molina-Vila, Jordi Bertran-Alamillo, Maria Gonzalez Cao, Xavier Gonzalez, Santiago Viteri Ramirez, Niki Karachaliou, Cristina Teixido, Maria Sanchez-Ronco, Francesc Tresserra, Maria Teresa Cusido, Rafael Fabregas, Rafael Rosell;

Association of non-disruptive P53 mutations with poor progression-free survival (PFS) in resected breast cancer treated with neoadjuvant chemotherapy.

Niki Karachaliou, R. Jonas A. Nilsson, Jordi Berenguer, Ana Gimenez Capitan, Pepijn Schellen, Cristina Teixido, Justine Leonie Kuiper, Esther Drees, Magda Grabowska, Marte van Keulen, Jihane M. Tannous, Danielle Heideman, Erik Thunnissen, Anne-Marie C. Dingemans, Santiago Viteri Ramirez, Bakhos A. Tannous, Ana Drozdowskyj, Egbert F. Smit, Thomas Wurdinger, Rafael Rosell; EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients.

Matthias Scheffler, Anne Maria Schultheis, Cristina Teixido, Sebastian Yves Friedrich Michels, Daniela Morales-Espinosa, Santiago Viteri, Sabine Merkelbach-Bruse, Rieke Fischer, Jana Fassunke, Martin Sebastian, Monika Heidi Serke, Winfried Randerath, Ulrich Gerigk, Yon-Dschun Ko, Stefan Krüger, Roland Schnell, Achim Rothe, Rafael Rosell, Reinhard Büttner, Juergen Wolf, ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability.

ASCO 2014
Niki Karachaliou, Ana Drozdowskyj, Ana Gimenez Capitan, Andres Felipe Cardona Zorrilla, Radj Gervais, Bartomeu Massuti, Teresa Moran, Margarita Majem, Enriqueta Felip, Enric Carcereny Costa, Rosario Garcia Campelo, Santiago Viteri Ramirez, Daniela Morales-Espinosa, Alberto Verlicchi, Elisabetta Crisetti, Imane Chaib, Jose Luis Ramirez, Patrick C. Ma, Rafael Rosell; Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients (p)

ASCO 2013
Trever Grant Bivona, Petros Giannikopoulos, Carlota Costa, Niki Karachaliou, Santiago Viteri, M. Rosario Garcia-Campelo, John St. John, Andrew V. Uzilov, Anne S. Wellde, William Reilly Polkinghorn, Margarita Majem, Enriqueta Felip, Enric Carcereny, Cordula Nicole Heidecke, Bartomeu Massuti, George W. Wellde, Jonathan S. Weissman, Rafael Rosell, Integrated genomic analysis of EGFR-mutant non-small cell lung cancer immediately following erlotinib initiation in patients.

ASCO 2012
Sanjay Goel, Teresa Moran, Cinthya Coronado, Santiago Viteri Ramirez, Imran Chaudhary, Mohammad Haroon Ghalib, Umang Swami, Yijuan Hou, Enric Carcereny, Jose Alcantara, Jorge Luis Iglesias Dios, Bernardo De Miguel, Cristina Buges, Rafael Rosell; Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors.

Enric Carcereny Costa, Miquel Taron, Cristina Queralt, Itziar de Aguirre, Laia Capdevila, Sara Cros, Alain Vergnenegre, Filippo De Marinis, Bartomeu Massuti, Noemi Reguart, Mayumi Ono, Cristina Buges, Mariano Provencio, Pilar Garrido López, Santiago Viteri Ramirez, Amaya Gasco, Jose Miguel Sanchez, Manuel Cobo, Ana Drozdowskyj, Rafael Rosell; Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study

ASCO 2011
M. Taron, S. Benlloch, R. Rosell, J. J. Sanchez, C. Costa, A. Gimenez Capitan, C. Mayo, J. Bertran-Alamillo, M. A. Molina, B. Massuti, C. Camps, M. Majem, D. Isla, M. Santarpia, S. Viteri, A. Gasco, T. Moran, E. Carcereny, C. Queralt, I. de Aguirre; Identification of AEG-1 and BARD1 as predictors of erlotinib outcome in EGFR-mutant non-small cell lung cancer (NSCLC) by NanoString multiple target profiling

M. Santarpia, M. Sanchez-Ronco, I. Magri, S. Viteri, C. Costa, A. Gasco, M. Gonzalez Cao, N. Mederos, F. Salazar, J. Bertran-Alamillo, A. Gimenez Capitan, G. Altavilla, S. Benlloch, Z. Yeste, E. Aldeguer, M. Taron, R. Rosell; The nuclear factor kB (NFkB) and Notch signaling pathways and BRCA1 mRNA expression in stage IV non-small cell lung cancer (NSCLC) patients (p).

S. Viteri, R. Rosell, C. Costa, M. Taron, J. J. Sanchez, S. Benlloch, T. Moran, B. Massuti, C. Camps, M. Majem, E. Carcereny, F. Cardenal, A. Gasco, N. Mederos, I. Magri, C. D. Rolfo, M. R. Garcia-Campelo, A. Gimenez Capitan, I. de Aguirre, C. Queralt; Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations.

S. Viteri, R. Rosell, C. Costa, M. Taron, J. J. Sanchez, S. Benlloch, T. Moran, B. Massuti, C. Camps, M. Majem, E. Carcereny, F. Cardenal, A. Gasco, N. Mederos, I. Magri, C. D. Rolfo, M. R. Garcia-Campelo, A. Gimenez Capitan, I. de Aguirre, C. Queralt; Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations

ECCO 2005

S. Viteri, A. Viudez, J. Rodríguez, M. Gonzalez Cao et al. "Capecitabine, oxaliplatin and irinotecan combination: a first line treatment for metastasic colorectal cancer, preliminary results of a phase II study"
Diaz Lagares A, Viteri Ramírez S, González Cao M, López González AS, Varo Canarruzabeitia N, González Hernández A. "Estudio de los marcadores tumorales S-100B y MIA en el estadiaje de melanoma". Congreso de la Sociedad española de bioquímica clínica y patología molecular. 19-21 Octubre 2005, Valladolid. Publicado Química Clínica 2005; 24(5), abstr 376